0001662579-24-000024.txt : 20240308 0001662579-24-000024.hdr.sgml : 20240308 20240308191908 ACCESSION NUMBER: 0001662579-24-000024 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240307 FILED AS OF DATE: 20240308 DATE AS OF CHANGE: 20240308 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Siegel Jolie CENTRAL INDEX KEY: 0001768223 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39567 FILM NUMBER: 24736186 MAIL ADDRESS: STREET 1: C/O NEON THERAPEUTICS, INC. STREET 2: 40 ERIE ST., SUITE 110 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: C4 Therapeutics, Inc. CENTRAL INDEX KEY: 0001662579 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 475617627 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 490 ARSENAL WAY STREET 2: SUITE 120 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: (617) 231-0700 MAIL ADDRESS: STREET 1: 490 ARSENAL WAY STREET 2: SUITE 120 CITY: WATERTOWN STATE: MA ZIP: 02472 4 1 wk-form4_1709943540.xml FORM 4 X0508 4 2024-03-07 0 0001662579 C4 Therapeutics, Inc. CCCC 0001768223 Siegel Jolie C/O C4 THERAPEUTICS, INC. 490 ARSENAL WAY #120 WATERTOWN MA 02472 0 1 0 0 Chief Legal Officer 0 Stock Option (Right to Buy) 45.54 2024-03-07 4 D 0 84850 0 D 2031-02-10 Common Stock 84850 0 D Stock Option (Right to Buy) 19 2024-03-07 4 A 0 84850 0 A 2031-02-10 Common Stock 84850 84850 D Stock Option (Right to Buy) 22.71 2024-03-07 4 D 0 90000 0 D 2032-02-13 Common Stock 90000 0 D Stock Option (Right to Buy) 19 2024-03-07 4 A 0 90000 0 A 2032-02-13 Common Stock 90000 90000 D On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. This option shall vest and become exercisable in 16 equal quarterly installments, with the first installment vesting on May 11, 2021. The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2022. /s/ Jolie M. Siegel 2024-03-08